12-hydroxy-octadecanoic acid hydrazide | 16169-50-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 12-hydroxy-octadecanoic acid hydrazide
• 英文别名: 12-Hydroxy-stearinsaeure-hydrazid；12-Hydroxy-octadecansaeure-hydrazid；12-Hydroxyoctadecanehydrazide
• CAS: 16169-50-9
• 化学式: C₁₈H₃₈N₂O₂
• 分子量: 314.512
• InChiKey: QXYCQIBSHISYMA-UHFFFAOYSA-N

物化性质

• 熔点：
  115.5-116.5 °C
• 沸点：
  480.3±18.0 °C(Predicted)
• 密度：
  0.944±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  12-hydroxy-octadecanoic acid hydrazide 在 乙醇 、 碘 作用下， 生成 N,N'-bis-(12-hydroxy-octadecanoyl)-hydrazine
  参考文献：
  名称：

  Attenuation of Verapamil-induced Myocardial Toxicity in an Ex-vivo Rat Model Using a Verapamil-specific Ovine Immunoglobin

  摘要：

  Abstract Objective: To determine whether an ovine verapamil‐specific immunoglobin G (V‐IgG) attenuates verapamil toxicity in an ex‐vivo rat left ventricular papillary muscle model. Methods: The authors dissected left ventricular papillary muscle strips from male Sprague‐Dawley rats (350‐410 g) and suspended them in an oxygen‐perfused Tyrode buffer bath at 37.5°C. Muscle strips equilibrated for 90 minutes under electrical stimulation of 1 Hz. Resting and developed tension (mg) were monitored continuously. A concentration—response trial was performed with verapamil concentrations ranging from 31 to 1,020 nM; 510 nM produced consistent reduction in developed tension. A trial of V‐IgG was then conducted by administering the following treatments to papillary muscle strips in a randomized manner: V‐IgG + 510 nM verapamil, nonspecific ovine IgG (N‐IgG) + 510 nM verapamil (protein control), and 510 nM verapamil alone. Immunoglobin G was administered in equimolar concentrations to verapamil. Attenuation was expressed as inhibition of the verapamil‐induced reduction of developed tension. Results: The V‐IgG comparative trial indicated the V‐IgG + verapamil treatment had a mean reduction in developed tension of 14.1% (SD ± 12.2) compared with 36.2% (SD ± 14.9) for N‐IgG + verapamil and 34.9% (SD ± 8.1) for verapamil alone (p < 0.05). There was no difference between the two control groups. Conclusion: Verapamil‐specific IgG attenuated verapamil‐induced reduction of developed tension in an ex‐vivo rat model.

  DOI：

  10.1111/j.1553-2712.2001.tb01092.x
• 作为产物：
  描述：

  12-羟基硬脂酸 在 一水合肼 作用下， 生成 12-hydroxy-octadecanoic acid hydrazide
  参考文献：
  名称：

  Attenuation of Verapamil-induced Myocardial Toxicity in an Ex-vivo Rat Model Using a Verapamil-specific Ovine Immunoglobin

  摘要：

  Abstract Objective: To determine whether an ovine verapamil‐specific immunoglobin G (V‐IgG) attenuates verapamil toxicity in an ex‐vivo rat left ventricular papillary muscle model. Methods: The authors dissected left ventricular papillary muscle strips from male Sprague‐Dawley rats (350‐410 g) and suspended them in an oxygen‐perfused Tyrode buffer bath at 37.5°C. Muscle strips equilibrated for 90 minutes under electrical stimulation of 1 Hz. Resting and developed tension (mg) were monitored continuously. A concentration—response trial was performed with verapamil concentrations ranging from 31 to 1,020 nM; 510 nM produced consistent reduction in developed tension. A trial of V‐IgG was then conducted by administering the following treatments to papillary muscle strips in a randomized manner: V‐IgG + 510 nM verapamil, nonspecific ovine IgG (N‐IgG) + 510 nM verapamil (protein control), and 510 nM verapamil alone. Immunoglobin G was administered in equimolar concentrations to verapamil. Attenuation was expressed as inhibition of the verapamil‐induced reduction of developed tension. Results: The V‐IgG comparative trial indicated the V‐IgG + verapamil treatment had a mean reduction in developed tension of 14.1% (SD ± 12.2) compared with 36.2% (SD ± 14.9) for N‐IgG + verapamil and 34.9% (SD ± 8.1) for verapamil alone (p < 0.05). There was no difference between the two control groups. Conclusion: Verapamil‐specific IgG attenuated verapamil‐induced reduction of developed tension in an ex‐vivo rat model.

  DOI：

  10.1111/j.1553-2712.2001.tb01092.x

文献信息

• [EN] (R)-12-HYDROXYSTEARIC ACID HYDRAZIDES AS GELATORS AND SELF-STANDING GELS THEREOF<br/>[FR] HYDRAZIDES D'ACIDE (R)-12-HYDROXYSTÉARIQUE UTILISÉS COMME GÉLIFIANTS ET LEURS GELS AUTOPORTEURS
  申请人：UNIV GEORGETOWN

  公开号：WO2017117212A1

  公开（公告）日：2017-07-06

  (R)-12-hydroxystearic acid hydrazides as gelators and gels generated therefrom are provided. A series of (R)-12-hydroxystearic acid hydrazides produce gels that are self-standing and self-healing. The (R)-12-hydroxystearic acid hydrazides are capable of exhibiting gelling properties in a wide variety of solvents. The gels have demonstrated good potential for use in drug release.

  提供(R)-12-羟基硬脂酸腙作为凝胶剂及由此产生的凝胶。一系列(R)-12-羟基硬脂酸腙产生的凝胶具有自立和自修复性质。这些(R)-12-羟基硬脂酸腙能够在各种溶剂中展现凝胶特性。这些凝胶已经展示出在药物释放中的潜力。
• Deodorizing agent and resin composition
  申请人：Polyplastics Co., Ltd.

  公开号：EP1595918A1

  公开（公告）日：2005-11-16

  A deodorizing agent comprises at least one hydrazine compound selected from a polycarboxylic acid hydrazide having a hydroxyaryl group, a hydrazide of a hydroxyarylalkanecarboxylic acid, a non-acrylic polyhydrazide and an aminourazole compound. The deodorizing agent is useful for efficiently deodorizing an aldehyde odor. The deodorizing agent may further comprise a deodorizing auxiliary (a basic nitrogen-containing compound, a weak acid or a metal salt thereof, a metal compound, an alcohol, a polyphenol, an adsorbent inorganic compound) and may used as a resin composition in combination with a resin. The resin composition may further comprise an antioxidant, a heat stabilizer, a processing stabilizer, a weather (light)-resistant stabilizer, a gloss-controlling agent, a slip-improving agent, a coloring agent, a filler or the like. Such a composition ensures to inhibit an aldehyde odor efficiently and capture or scavenge an aldehyde certainly, without deteriorating resin properties even when a deodorizing agent is mixed with a polyacetal-series resin or the like.

  除臭剂包括至少一种肼化合物，选自具有羟基芳基的聚羧酸肼、羟基芳基烷羧酸肼、非丙烯酸聚肼和氨基脲唑化合物。除臭剂可用于有效去除醛类气味。除臭剂可进一步包含除臭辅助剂（含氮碱性化合物、弱酸或其金属盐、金属化合物、醇、多酚、吸附性无机化合物），并可作为树脂组合物与树脂结合使用。树脂组合物还可以包括抗氧化剂、热稳定剂、加工稳定剂、耐候（光）稳定剂、光泽控制剂、滑爽剂、着色剂、填料等。这样的组合物即使在除臭剂与聚缩醛系列树脂等混合的情况下，也能确保有效抑制醛气味并捕捉或清除醛，而不会降低树脂的性能。
• POLYACETAL RESIN COMPOSITION
  申请人：Polyplastics Co., Ltd.

  公开号：EP1674526A1

  公开（公告）日：2006-06-28

  A polyacetal resin composition comprises a polyacetal resin, and at least one carboxylic acid hydrazide selected from a saturated or unsaturated long-chain aliphatic carboxylic acid hydrazide, a saturated or unsaturated alicyclic carboxylic acid hydrazide, a dimer acid or trimer acid hydrazide, and an oxycarboxylic acid hydrazide corresponding to each of these hydrazides. The proportion of the carboxylic acid hydrazide may be about 0.001 to 20 parts by weight relative to 100 parts by weight of the polyacetal resin. The polyacetal resin composition may further comprise at least one member selected from an antioxidant, a heat stabilizer, a processing stabilizer, a weather (light)-resistant stabilizer, an impact resistance improver, a slip-improving agent, a coloring agent, and a filler. With the use of such a resin composition, stability of a polyacetal resin is improved, and formaldehyde emission is inhibited.

  聚缩醛树脂组合物由聚缩醛树脂和至少一种羧酸酰肼组成，羧酸酰肼选自饱和或不饱和长链脂族羧酸酰肼、饱和或不饱和脂环族羧酸酰肼、二聚酸或三聚酸酰肼以及与上述每种酰肼相对应的氧羧酸酰肼。相对于 100 重量份的聚缩醛树脂，羧酸酰肼的比例可以是约 0.001 至 20 重量份。聚缩醛树脂组合物还可以包含至少一种选自抗氧化剂、热稳定剂、加工稳定剂、耐候（光）稳定剂、抗冲击性改进剂、滑爽性改进剂、着色剂和填料的成分。使用这种树脂组合物可以提高聚缩醛树脂的稳定性，并抑制甲醛释放。
• POLYACETAL RESIN COMPOSITION AND MOLDED ARTICLE THEREOF
  申请人：Polyplastics Co., Ltd.

  公开号：EP1688461A1

  公开（公告）日：2006-08-09

  A polyacetal resin composition comprises a polyacetal resin having a trioxane content of not more than 100 ppm (preferably not more than 50 ppm, and more preferably not more than 10 ppm) and at least one stabilizer selected from the group consisting of an antioxidant, a formaldehyde emission inhibitor, a processing stabilizer and a heat stabilizer. The polyacetal resin may be a polyacetal resin (particularly a polyacetal copolymer) in which the trioxane amount is reduced by a solvent treatment and/or a heat treatment. Moreover, the polyacetal resin composition may further contain at least one additive selected from the group consisting of a weather(light)-resistantstabilizer, an impact resistance improver, a gloss control agent, a sliding improver, a coloring agent, and a filler. Such a polyacetal resin composition can reduce the amount of trioxane elution and/or the amount of a volatile organic compound from a molded product thereof.

  一种聚缩醛树脂组合物包括一种三氧杂环戊烷含量不超过 100 ppm（最好不超过 50 ppm，最好不超过 10 ppm）的聚缩醛树脂，以及至少一种选自抗氧化剂、甲醛释放抑制剂、加工稳定剂和热稳定剂的稳定剂。聚缩醛树脂可以是聚缩醛树脂（特别是聚缩醛共聚物），其中的三氧杂环戊烷含量通过溶剂处理和/或热处理而减少。此外，聚缩醛树脂组合物还可进一步含有至少一种添加剂，这些添加剂选自耐候（光） 稳定剂、抗冲击性改进剂、光泽控制剂、滑动性改进剂、着色剂和填料组成的组。这种聚缩醛树脂组合物可以减少其模塑产品中的三氧杂烷洗脱量和/或挥发性有机化合物的含量。
• Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin
  申请人：Polyplastics Co., Ltd.

  公开号：EP1867667A1

  公开（公告）日：2007-12-19

  The present invention provides an agent to decompose unstable terminal group, which is effective in a small adding amount, which sufficiently decreases the quantity of residual unstable terminal group, and which generates very little limitation on the treatment method, the apparatus, and the use amount of the agent. Specifically, it provides a method for manufacturing stabilized polyacetal resin having the step of applying heat treatment to a polyacetal resin having an unstable terminal group in the presence of an agent to decompose the unstable terminal group, which agent is composed of a heterocyclic quaternary ammonium salt, thus decreasing the quantity of the unstable terminal group.

  本发明提供了一种分解不稳定末端基团的药剂，其添加量小，效果好，能充分减少残留的不稳定末端基团的数量，并且对处理方法、装置和药剂的使用量限制很小。具体地说，它提供了一种制造稳定聚缩醛树脂的方法，该方法的步骤是：在有药剂存在的情况下，对具有不稳定末端基团的聚缩醛树脂进行热处理，以分解不稳定末端基团，该药剂由杂环季铵盐组成，从而减少不稳定末端基团的数量。